Skip to content

Pericapsular Nerve Group Block Chemical Neurolysis in Advanced Hip Osteoarthritis

The Impact of the Pericapsular Nerve Group Block (PENG) Chemical Neurolysis on the Quality of Life of Patients with Advanced Hip Osteoarthritis. a Randomized, Prospective Double-blinded Clinical Trial.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06087588
Acronym
PENG
Enrollment
100
Registered
2023-10-18
Start date
2023-10-17
Completion date
2025-01-14
Last updated
2025-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Osteoarthritis, Hip

Brief summary

PENG neurolysis in advanced osteoarthritis of the hip joint.

Detailed description

The study aims to assess the safety and effectiveness of regional pain treatment methods and their impact on the quality of life of patients with advanced osteoarthritis of the hip joint.

Interventions

PENG sham block with 20ml 0,9% normal saline

PENG neurolysis with 2.5ml of 95% ethanol

Sponsors

Poznan University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Intervention model description

Group 1 - PENG sham block Group 2 - PENG neurolysis 95% ethanol

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Patients of the Pain Treatment Clinic of the Transfiguration of Jesus Clinical Hospital of the Medical University of Poznań will be qualified for the study * patients with coxarthrosis or gonarthrosis who failed to achieve satisfactory pain control (NRS\>3) despite the use of NSAIDs, Paracetamol, and co-analgetics * Age of patients: from 18 to 110 years of age. * Caucasian patients can give informed, complete, written consent.

Exclusion criteria

* suspected or diagnosed opioid dependence syndrome * active cancer * dementia

Design outcomes

Primary

MeasureTime frameDescription
NRS score7 days after procedureThe NRS (Numeric Pain Rating Scale) is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of his/her pain.

Secondary

MeasureTime frameDescription
Health Questionnaire (EQ-5D-5L)7 days after procedureThe descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state
neurological deficits7 days after procedureyes/no
total opioid consumption7 days after proceduremilligrams of oral morphine per day

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026